PureTech Health plc (0VQ.F)
- Previous Close
2.5800 - Open
2.4400 - Bid 2.4800 x --
- Ask 2.6000 x --
- Day's Range
2.4400 - 2.4400 - 52 Week Range
1.6040 - 2.7600 - Volume
1,500 - Avg. Volume
102 - Market Cap (intraday)
-- - Beta (5Y Monthly) 0.93
- PE Ratio (TTM)
-- - EPS (TTM)
-0.2020 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
PureTech Health plc, a clinical stage biotherapeutics company, engages in the discovery, development, and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, currently under Phase 3 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, to inhibit the activity of galectin-9 for treating solid tumors and hematological malignancies. It is also developing LYT-300, an oral allopregnanolone, currently completed Phase 1 stage, to treat depression, anxiety, and related indications; and LYT-310, an oral cannabidiol, currently under preclinical stage, to treat epilepsies and other neurological indications. In addition, the company is developing LYT-503/IMB-150, a non-opioid inflammation targeted disease immunomodulation for the potential treatment of interstitial cystitis, or bladder pain syndrome; and Glyph technology platform, a lymphatic-targeting chemistry platform, which leverages the body's natural lipid absorption and transports the process to orally administer drugs via the lymphatic system. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
www.puretechhealth.com96
Full Time Employees
December 31
Fiscal Year Ends
--
Sector
--
Industry
Recent News: 0VQ.F
Performance Overview: 0VQ.F
Trailing total returns as of 4/27/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 0VQ.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 0VQ.F
Valuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-13.09%
Return on Equity (ttm)
-13.25%
Revenue (ttm)
3.33M
Net Income Avi to Common (ttm)
-65.7M
Diluted EPS (ttm)
-0.2020
Balance Sheet and Cash Flow
Total Cash (mrq)
327.14M
Total Debt/Equity (mrq)
29.57%
Levered Free Cash Flow (ttm)
-114.8M
Company Insights: 0VQ.F
0VQ.F does not have Company Insights